Request Demo
Last update 23 Jan 2025
NEO-PV-01
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Personalized antigen vaccine, Synthetic peptide vaccine, Therapeutic vaccine |
Synonyms Neo Vax, Neoantigen vaccine, Neoantigen-based vaccine + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
12
Clinical Trials associated with NEO-PV-01NCT03361852
A Pilot Study of a Personalized Neoantigen Cancer Vaccine in Combination With Pembrolizumab Following Front-Line Rituximab in Follicular Lymphoma
NCT04930783
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma
NCT03219450
A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.
100 Clinical Results associated with NEO-PV-01
Login to view more data
100 Translational Medicine associated with NEO-PV-01
Login to view more data
100 Patents (Medical) associated with NEO-PV-01
Login to view more data
204
Literatures (Medical) associated with NEO-PV-0101 Jan 2025NEOPLASIA
Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity
Article
Author: Liu, Jiajun ; Zhou, Qiao ; Sun, Qinying ; Ning, Yunye ; Cheng, Lan ; Wang, Jun ; Qin, Hao ; Xia, Yang ; Zhao, Bi ; Su, Xiaoping ; Dong, Yuchao ; Feng, Tangtao ; Huang, Ruichen ; Zhou, Haosu ; Liu, Yanfang ; Song, Xiuyan ; Zhang, Wei ; Jiao, Yang
BACKGROUND:
The neoantigen vaccine has remarkable potential in treating advanced cancer due to its tumor specificity and ability to bypass central tolerance mechanisms. However, numerous neoantigens show poor immunogenicity, and the immune inhibitory factors of present in both tumors and tumor-draining lymph nodes impair the efficacy of cancer neoantigen vaccine. Eliminating immunosuppressive cells will improve the priming and expansion of anti-tumor immune cells induced by the vaccine.
METHODS:
In this study, a Treg-depleting regimen (consisting of CD25mAb and low-dose cyclophosphamide (LD-CTX)) was used in conjunction with a neoantigen vaccine for treating mice with solid tumors. We constructed two types of tumor models and investigated differences in therapy efficacy in the four groups (PBS, vaccine, CD25mAb+CTX and combination) at the genetic and protein levels. ELISPOT and TCR sequencing were applied to detect the expansion of neoantigen reactive T cells (NRT) and tumor antigen spreading.
RESULTS:
In the combinational group, the ELISPOT results showed an obvious expansion of NRT cells induced by weak immunogenic peptides. The combinational group exhibited significant improvement in inhibiting the tumor growth extended the survival time of tumor-bearing mice, and promoted T cells infiltration into tumors. Besides, compared to the Vac group, more neoantigen-targeted and TAA-targeted T cells were detected in the combinational group by TCR sequencing. The results of transcriptomic sequencing and flow cytometry showed that the number of Tregs in the combinational group was lower, while the proportions of memory effector T cells and effector T cells were higher than those in the vaccine group. An increase in mature DCs was also observed in vaccinated mice after receiving this Treg-depleting strategy.
CONCLUSION:
Our research first revealed that inhibiting the normal function of Tregs transformed "weaker" neoantigens into "stronger" ones, while also contributing to the proliferation of NRT cells. This Treg-depleting strategy allowed neoantigens with poor immunogenicity to elicit a robust immune response, thereby augmenting the efficacy of the neoantigen vaccine in delaying tumor growth and prolonging the survival of the hosts.
01 Dec 2024VACCINE
Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome
Article
Author: Blasco, Ana ; de la Fuente, Jorge ; Sánchez-Galarraga, Icíar ; Gómez-Lozano, Natalia ; García-Gómez, Sergio ; Pérez-Redondo, Marina ; Royuela, Ana ; Sánchez-Arjona, Alberto ; González, Elisa ; Silva, Lorenzo ; Anel, Jorge
BACKGROUND:
The COVID-19 pandemic adversely affected the severity and prognosis of patients with acute myocardial infarction (MI) caused by atherothrombosis (type 1 MI). The effect, if any, of COVID-19 vaccination and natural SARS-CoV2 serologic immunity in these patients is unclear. Our aim was to analyze the association between the severity and outcome of patients with type 1 MI and their previous SARS-CoV2 vaccination and serostatus.
METHODS:
A single-center retrospective cohort study conducted between March 1, 2020 and March 1, 2023. Clinical and follow-up information was collected from medical records and patients. Total antibodies (IgM, IgA, IgG) to nucleocapsid (N) antigens were measured by ECLIA (electrochemiluminescence-based immunoassay) to test the immune response to natural infection. If positive, IgM and IgG antibodies to spike (S) surface antigens were measured by CLIA to test the immune response to vaccine or natural infection. Multivariable logistic regression analysis was performed, adjusting for age, sex, hypertension, diabetes, and dyslipidemia.
RESULTS:
Total sample of 949 patients, 656 with ST-segment elevation MI (STEMI) and 293 with non-ST-segment elevation MI (NSTEMI). Mean age was 64 (SD 13) years, 80 % men. Pre-admission vaccination status was: ≥ 1 dose, 53 % of patients; complete vaccination, 49 %; first booster dose, 25 %. The majority (84 %) of vaccines administered were mRNA-based. Six months after MI, 92 (9.7 %) patients had a major adverse cardiac event (MACE) and 50 died; 11 % of patients had severe heart failure or cardiogenic shock (Killip III-IV) after STEMI. Vaccinated patients with STEMI and positive serology (Pos/Vax group) had a higher risk of Killip III-IV on admission: OR 2.63 (1.27-5.44), p = 0.010. SARS-CoV-2 S-specific IgG titers were highest in this group (median > 2080 AU/mL, [IQR 1560- >2080] vs 91 [32-198] in the unvaccinated group). In the overall sample, a higher incidence of 6-month MACE was not demonstrated (OR 1.89 [0.98-3.61], p = 0.055).
CONCLUSIONS:
The combination of vaccination and natural SARS-CoV2 infection was associated with the development of severe heart failure and cardiogenic shock in patients with STEMI, possibly related to an increased serological response.
01 Dec 2024JOURNAL OF PUBLIC HEALTH
International relations in public health: the Pentagon’s anti-vax campaign during COVID-19 pandemic
Article
Author: Regilme Jr, Salvador Santino F
100 Deals associated with NEO-PV-01
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Follicular Lymphoma | Phase 1 | US | 14 Mar 2022 | |
| Chronic Lymphocytic Leukemia | Phase 1 | US | - | 17 Aug 2021 |
| Ovarian Cancer | Phase 1 | US | 20 Nov 2020 | |
| Renal Cell Carcinoma | Phase 1 | US | 03 Mar 2019 | |
| Glioblastoma | Phase 1 | US | - | 11 Oct 2018 |
| Metastatic melanoma | Phase 1 | US | 08 Oct 2018 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 1 | US | 04 May 2018 | |
| Bladder Cancer | Phase 1 | US | 01 Oct 2016 | |
| Melanoma | Phase 1 | US | 01 Oct 2016 | |
| Non-Small Cell Lung Cancer | Phase 1 | US | 01 Oct 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03380871 (Pubmed) Manual  | Phase 1 | Non-squamous non-small cell lung cancer First line | 38 | tqjxzuqggk(djqungdnqd) = vkiugakfgx xkdfqxdydr (jbmlsfxexz ) | Positive | 17 Aug 2022 | |
Phase 1 | Squamous non-small cell lung cancer First line | 38 | mnjmtzjiso(hgoybvttoc) = zvairlvixs vumbobryhi (tyvluvkiux, 5.6 - 16.8) View more | Positive | 01 Jul 2021 | ||
mnjmtzjiso(hgoybvttoc) = jlflzuhuzh vumbobryhi (tyvluvkiux, 5.6 - 16.8) View more | |||||||
Phase 1 | Squamous non-small cell lung cancer First line | 38 | yoplrxmgnx(haggyrolhv) = djmoqzypoc abulwasype (tknesgwfum ) View more | Positive | 10 Dec 2020 | ||
yoplrxmgnx(haggyrolhv) = ebuippzpui abulwasype (tknesgwfum ) View more | |||||||
Phase 1 | Neoplasms RECON tumor neoantigen abundance | peripheral TCR repertoires | - | NEO-PV-01 + adjuvant | stnbdqdefx(qmwomxgqrm) = eprlvjtvdq gafuzapkid (tnqhbpdnvu ) View more | Positive | 01 Nov 2019 | |
stnbdqdefx(qmwomxgqrm) = rrwinyxhxf gafuzapkid (tnqhbpdnvu ) View more | |||||||
Phase 1 | 31 | NEO-PV-01 vaccine plus adjuvant Poly-ICLC | rsneztjjzy(yirfoezpyb) = pixdwpiqic bvufirbgjj (hhsywxafbc ) | Positive | 22 Oct 2018 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free